TNF and psoriasis: Latent Mtb infection also poses iatrogenic clinical challenges, due to increases in TB reactivation following administration of biologicals, such as tumor necrosis factor-alpha (TNFα)/IL-12/IL-23 blockers in treating inflammatory diseases like rheumatoid arthritis, Crohn's disease, and psoriasis [21].